Peptide profile · Weight Management
Lixisenatide
Short-acting prandial GLP-1 receptor agonist for postprandial glucose control
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
20 mcg
Half-life
2.8-3 hours
Bioavailability
55% subcutaneous bioavailability
Molecular weight
4,858 Da
Evidence level
Strong human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C215H347N61O65S
Primary benefits
Powerful postprandial glucose reduction through GLP-1 receptor activation, delayed gastric emptying, and glucose-dependent insulin secretion
Demonstrated cardiovascular safety in the ELIXA trial with no increased risk of major adverse cardiovascular events
Modest weight reduction through appetite suppression and delayed gastric emptying, though less pronounced than long-acting GLP-1 RAs
Sanofi
Amino acid sequence
Hexanoyl-GDGQYTLTSIFTDVSSYLEG-Q-AAKEFIAWLVRGK-G02 · Dosing
How much do I take?
20 mcg · once daily
Subcutaneous: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
Best time to take
Administer Lixisenatide at the same time each day (or on the same day each week for weekly injections). Many users prefer morning or evening administration. Pick a time you'll remember consistently.
With food?
Lixisenatide injections can be given regardless of meal timing. However, if GI effects occur, administering on an empty stomach or with a light meal may help reduce discomfort.
If stacking
Lixisenatide should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
－ Decrease if
- −Side effects are bothersome or impacting daily life despite management strategies
- −You experience any signs of an adverse reaction
- −Lab results indicate the need for dose reduction
- −Your healthcare provider recommends a lower dose based on your response
✓ Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for managing postprandial hyperglycemia in type 2 diabetes & improving glycemic control as add-on to oral antidiabetics
Best for
Managing postprandial hyperglycemia in type 2 diabetes
Lixisenatide is particularly well-suited for individuals focused on managing postprandial hyperglycemia in type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving glycemic control as add-on to oral antidiabetics
Lixisenatide is particularly well-suited for individuals focused on improving glycemic control as add-on to oral antidiabetics. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting weight management in T2DM patients
Lixisenatide is particularly well-suited for individuals focused on supporting weight management in t2dm patients. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Combination therapy with basal insulin glargine
Lixisenatide is particularly well-suited for individuals focused on combination therapy with basal insulin glargine. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Lixisenatide with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
subcutaneous injection
Reconstitution — what you need
Example
Add the recommended volume of bacteriostatic water to the Lixisenatide vial. Gently swirl (do not shake) until the powder is fully dissolved. The resulting solution should be clear. Calculate your individual dose based on the concentration and your prescribed amount.
Your dose of Lixisenatide is determined by your healthcare provider. Using an insulin syringe marked in units, draw up the exact amount prescribed. For example, if the reconstituted concentration is 1mg/mL and your dose is 0.5mg, draw up 0.5mL (50 units on an insulin syringe). Always double-check calculations before injection.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
Technique
- 01Wash your hands thoroughly with soap and water before handling supplies
- 02Clean the injection site with an alcohol swab and let it air dry completely
- 03Pinch a fold of skin at the chosen injection site
- 04Insert the needle at a 45-90 degree angle (depending on needle length and body composition)
- 05Inject the medication slowly and steadily over 5-10 seconds
- 06Release the skin fold and remove the needle, applying gentle pressure with a clean swab
- 07Rotate injection sites to prevent tissue irritation or lipodystrophy
- 08Dispose of the needle safely in a sharps container—never recap or reuse needles
Storage · before reconstitution
Store Lixisenatide in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Lixisenatide should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
4 common side effects · 2 serious
Lixisenatide (Lyxumia, Adlyxin) is an FDA and EMA-approved GLP-1 receptor agonist with safety data from Phase 3 trials (LEAD program, 2012-2013) involving 4,000+ patients with type 2 diabetes. Gastrointestinal side effects (nausea, vomiting) are most common during dose escalation (30-40% of patients) but typically resolve after 2-3 weeks of stable dosing. The short half-life (3 hours) compared to longer-acting GLP-1 agonists means side effects have rapid onset and offset. No serious adverse events exceed background diabetes population rates in pivotal trials.
Lixisenatide safety is established through GetGoal Phase 3 trials published in Diabetes Care and American Journal of Cardiovascular Disease, demonstrating cardiovascular safety with HbA1c reductions of 0.5-1.5%. Post-marketing surveillance by EMA and FDA shows favorable tolerability profile consistent with GLP-1 agonist class. Medullary thyroid carcinoma and pancreatitis risks remain theoretical (based on preclinical data) with no clinical cases in therapy-exposed populations.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Lixisenatide
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Lixisenatide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Insulin Glargine — FDA-approved fixed-ratio combination (Soliqua 100/33) for complementary fasting and postprandial glucose control
- ✓Metformin — First-line combination providing complementary mechanisms for glycemic control and insulin sensitization
- ✓SGLT2 Inhibitors — Complementary glucose-lowering via insulin-independent renal glucose excretion with added cardiorenal benefits
With medications
- !Other GLP-1 Receptor Agonists — Redundant mechanism of action with increased gastrointestinal side effects and no additional benefit
- !DPP-4 Inhibitors — Overlapping incretin pathway stimulation provides minimal additional glucose-lowering effect
- !Pramipexole — Potential delayed absorption of oral medications due to gastric emptying effects of lixisenatide
With supplements
- ✓Multivitamins — Generally safe to take alongside Lixisenatide. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
06 · Effectiveness
How do I know it's working?
Strong human trials · first signs weeks 1-2
Evidence level
Strong human trials
(Phase 3 or FDA approved)
How it works
Lixisenatide is a once-daily GLP-1 hormone that helps control blood sugar in people with type 2 diabetes by increasing insulin release, suppressing glucagon, and slowing stomach emptying to reduce appetite.
Lixisenatide is a 44-amino acid synthetic GLP-1 receptor agonist with ~50% sequence homology to human GLP-1, containing a DPP-4-resistant Gly2 substitution and N-terminal hexanoyl fatty acid modification. This modification extends its half-life to ~3 hours, enabling once-daily dosing. Lixisenatide binds to and activates the GLP-1 receptor on pancreatic beta cells to promote glucose-dependent insulin secretion, suppresses postprandial glucagon release in hyperglycemic states, delays gastric emptying to reduce nutrient absorption rate, and activates central GLP-1 receptors in the hypothalamus to promote satiety.
What to expect
Weeks 1-2
What you might notice
- •Initial postprandial glucose improvements, possible nausea as the body adjusts to GLP-1 receptor activation during the 10 mcg starting dose period
What's normal
- •Nausea, mild appetite reduction, and slight changes in bowel habits are common during this initiation phase
- •Some patients notice reduced hunger after meals within days
What's next
- →After 14 days at 10 mcg, dose increases to the full 20 mcg maintenance dose with further glycemic improvement expected
Weeks 3-8
What you might notice
- •More consistent postprandial glucose control at the full 20 mcg dose, GI side effects typically diminishing, early weight stabilization or modest loss
What's normal
- •Nausea should begin to subside significantly
- •Postprandial glucose readings will show improvement
- •Fasting glucose may improve modestly
- •Weight may begin a gradual downward trend
What's next
- →Continue treatment at 20 mcg daily
- →HbA1c measurements at 12-16 weeks will reflect the cumulative glycemic benefit
Weeks 12-24
What you might notice
- •Full glycemic benefit reflected in HbA1c reduction of 0
- •0%, sustained postprandial glucose improvements, potential weight loss of 1-3 kg
What's normal
- •GI side effects should be minimal or resolved
- •Glycemic control should be stable
- •Weight loss, if occurring, tends to plateau at modest levels compared to long-acting GLP-1 RAs
What's next
- →Assess overall treatment response with HbA1c
- →If targets not met, consider addition of basal insulin or transition to fixed-ratio combination (Soliqua)
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Lixisenatide over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
How does lixisenatide differ from long-acting GLP-1 agonists like semaglutide or liraglutide?+
Lixisenatide is classified as a short-acting GLP-1 receptor agonist with a half-life of about 3 hours, while long-acting agents like semaglutide have half-lives of days to a week. This means lixisenatide primarily targets postprandial (after-meal) glucose through potent gastric emptying delay, whereas long-acting agents provide more continuous GLP-1 receptor activation affecting both fasting and postprandial glucose. Long-acting agents generally produce greater HbA1c reduction and weight loss, but lixisenatide uniquely excels at controlling post-meal glucose spikes.
What is Soliqua and how does it relate to lixisenatide?+
Soliqua 100/33 is an FDA-approved fixed-ratio combination of insulin glargine (a long-acting basal insulin) and lixisenatide in a single injection pen. Each unit delivers 1 unit of insulin glargine and 1/3 mcg of lixisenatide. This combination leverages the complementary mechanisms — basal insulin controls fasting glucose while lixisenatide targets postprandial glucose — providing comprehensive glycemic control with less weight gain and hypoglycemia than insulin alone.
What did the ELIXA cardiovascular outcomes trial show?+
The ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial enrolled 6,068 patients with type 2 diabetes who had a recent acute coronary syndrome event. Over a median follow-up of 25 months, lixisenatide demonstrated cardiovascular safety with a hazard ratio of 1.02 (95% CI: 0.89-1.17) for MACE (major adverse cardiovascular events), meeting its primary noninferiority endpoint. While it did not show cardiovascular superiority, it confirmed that lixisenatide does not increase cardiovascular risk.
When should I take lixisenatide in relation to meals?+
Lixisenatide should be injected subcutaneously within one hour before the first meal of the day. Consistent timing relative to meals is important because its primary glucose-lowering mechanism involves delaying gastric emptying of the subsequent meal. Taking it at the same time each day, preferably before the largest meal, optimizes postprandial glucose control.
Can lixisenatide be used in type 1 diabetes?+
No, lixisenatide is not approved or recommended for type 1 diabetes. It is specifically indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise. Type 1 diabetes involves autoimmune destruction of beta cells, and GLP-1 receptor agonists work primarily by enhancing glucose-dependent insulin secretion from functioning beta cells.
Does lixisenatide affect the absorption of other oral medications?+
Yes, lixisenatide significantly delays gastric emptying, which can affect the absorption rate and timing of orally administered medications. Medications that require rapid GI absorption or have a narrow therapeutic window should be taken at least 1 hour before lixisenatide injection or 4 hours after. Oral contraceptives and antibiotics requiring consistent absorption should be carefully timed relative to lixisenatide dosing.
08 · Further reading
History & related research
History · since 2003
The Mealtime Guardian Built From Lizard DNA
Born from the same Gila monster venom as exenatide but redesigned with a tail of six extra amino acids, lixisenatide found its calling not as a blood sugar workhorse, but as a mealtime specialist — and eventually as half of a powerful combination drug.
Read the full history of LixisenatideStudied for